• Home →
  • News →
  • Sichenzia Ross Ference Carmel LLP represents Virax Biolabs Group Limited in a $5 Million Registered Direct Offering

Sichenzia Ross Ference Carmel LLP represents Virax Biolabs Group Limited in a $5 Million Registered Direct Offering

virax biolabs logo

Press Release – New York, NY – August 23, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax”), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, in a $5 million registered direct offering to certain institutional investors.

Virax issued an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The SRFC team was led by partners Greg Sichenzia, Barrett DiPaolo and Matt Siracusa and associate Benasz Hansotia

Related Posts

Sichenzia Ross Ference Carmel LLP Represents New Era Helium in De-SPAC Transaction and Nasdaq Listing

Sichenzia Ross Ference Carmel LLP represents Madison Global Partners, LLC in an Unsecured Senior Convertible Note and Warrant Offering up to $1 Million

Sichenzia Ross Ference Carmel LLP Represents D. Boral Capital in $1.7 Million Registered Direct Offering of SRM Entertainment

Sichenzia Ross Ference Carmel LLP Represents A.G.P/Alliance Global Partners in $8 Million Private Placement of TransCode Therapeutics
←Previous post Next post→